ReviewFrontiers in oncology2015
The ever-expanding immunomodulatory role of calreticulin in cancer immunity.
Review in Frontiers in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer.Journal of translational medicine · 2026Article
- Biomaterial-Based In Situ Cancer Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Optical biosensor based on weak measurement for ultra-sensitive detection of calreticulin in human serum.Biomedical optics express · 2024Article
- Mapping the cellular and molecular landscape of cardiac non-myocytes in murine diabetic cardiomyopathy.iScience · 2023Article
- Overcoming Resistance to Immune Checkpoint Inhibitor Therapy Using Calreticulin-Inducing Nanoparticle.Pharmaceutics · 2023Article
- The therapeutic mavericks: Potent immunomodulating chaperones capable of treating human diseases.Journal of cellular and molecular medicine · 2023Review
- Calreticulin Expression Controls Cellular Redox, Stemness, and Radiosensitivity to Function as a Novel Adjuvant for Radiotherapy in Neuroblastoma.Oxidative medicine and cellular longevity · 2023Article
- Advances in Intracellular Calcium Signaling Reveal Untapped Targets for Cancer Therapy.Biomedicines · 2021Review
- The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.Journal of immunology research · 2020Review
- Moonlighting Proteins Are Important Players in Cancer Immunology.Frontiers in immunology · 2020Review
- Long noncoding RNAs in cancer-immunity cycle.Journal of cellular physiology · 2018Review
- Molecular and Biochemical Characterization of Opisthorchis viverrini Calreticulin.The Korean journal of parasitology · 2017Article
- Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.Haematologica · 2017Article
- Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.Frontiers in immunology · 2017Review
- Expression and significance of calreticulin in human osteosarcoma.Cancer biomarkers : section A of Disease markers · 2017Article
- Article
- Pancreatic cancer: Update on immunotherapies and algenpantucel-L.Human vaccines & immunotherapeutics · 2016Review
- Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies.Oncotarget · 2015Review
- Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).Stem cell investigation · 2015Review
- Editorial: Endoplasmic Reticulum and Its Role in Tumor Immunity.Frontiers in oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calreticulin is a pleiotropic molecule that normally resides in the lumen of the endoplasmic reticulum (ER). Here, it has various functions, ranging from regulation of calcium homeostasis to ensuring proper protein folding. More recently, calreticulin gained special interest for its extracellular functions, where it has direct immunomodulatory activity. In this respect, calreticulin activates dendritic cells and macrophages. In addition, certain anti-cancer therapies induce the translocation of calreticulin from the ER to the cell surface of dying cancer cells, where calreticulin dictates the immunogenicity of these cells. Interestingly, treatment with tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) also induces membrane calreticulin exposure on cancer cells. As shown here, calreticulin directly interacts with TRAIL and its receptor-signaling complex, as well as with other TNF family members. Of note, TRAIL is a well known immunomodulatory molecule, and is expressed on the surface of natural killer T-cells. Therefore, calreticulin may have an as yet unrecognized wide(r) impact on immunity, with the TNF-ligand family modulating virtually all aspects of the immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.